BioSpace News Archive

AIM ImmunoTech Inc. announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research for the proposed AMP-COV-100 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, a critical step in the company’s ongoing efforts to develop Ampligen as a COVID-19 treatment.

OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Parker will oversee all aspects of commercial strategy, planning and operations for the company.

Following interim review of unblinded safety and efficacy data, independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 Opaganib targets a human cell component involved in viral replication and is therefore expected to be effective against emerging viral variants with mutations in the spike protein

Banjo Health’s clinician-designed Prior Authorization (PA) Management solution aids ELMCRx Solutions to minimize PA Turn-Around-Times and promote consistent determinations

On November 16, 2020, OncoZenge AB (publ), Moberg Pharma’s subsidiary, announced that the company had secured financing of a total of approximately SEK 70 million ahead of the spin-off and separate listing on Nasdaq First North Growth Market.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT®) Category III Code for transcatheter implantation of a coronary sinus reduction device.

Fact.MR, a global research firm, in its recent report on the global lip filler market shall register a steady CAGR in 2021 & beyond.

Recent developments in the healthcare sector has transformed and revolutionized the traditional health care system.

Rising incidences of cancer has boosted the market for radiotherapy. Based on the growing demand for the minimally invasive procedures, the global radiotherapy patient positioning market is projected to witness a substantial growth over the duration of 2019 to 2027.